Pay in 4 interest-free payments of $5.53 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Another agent who came to us just ran into this exact scenario with a term case last month
The grey-market supply situation adds a separate layer of uncertainty
These key studies clearly provided clinical proof-of-concept that blocking the catalytic activity of DPP-4 could be a viable approach to treat T2DM, whilst at the same time helped to allay concern over whether the metabolism of any other potential DPP-4 substrates might be affected to cause unwanted off-target effects
Key unanswered legal and operational questions include how bridge costs will be financed, effects on patient out-of-pocket limits, and overlap with forthcoming negotiated prices under the Medicare Drug Price Negotiation Program
US$ 25.45
US$ 27.44
US$ 28.11
